| Target Price | HK$17.24 |
| Price | HK$5.34 |
| Potential |
223.11%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Cstone Pharmaceuticals 2027 .
The average Cstone Pharmaceuticals target price is HK$17.24.
This is
223.11%
register free of charge
HK$21.00
293.63%
register free of charge
HK$9.95
86.48%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Cstone Pharmaceuticals to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cstone Pharmaceuticals stock has an average upside potential 2027 of
223.11%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million HK$ | 315.68 | 578.81 |
| 33.80% | 83.55% | |
| EBITDA Margin | -132.31% | -83.53% |
| 1,577.88% | 36.87% | |
| Net Margin | -162.10% | 9.13% |
| 623.75% | 105.63% |
5 Analysts have issued a sales forecast Cstone Pharmaceuticals 2026 . The average Cstone Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
6 Cstone Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Cstone Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | -0.37 | 0.04 |
| 362.50% | 110.81% | |
| P/E | 150.30 | |
| EV/Sales | 12.97 |
6 Analysts have issued a Cstone Pharmaceuticals forecast for earnings per share. The average Cstone Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Cstone Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


